Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 72 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer... March 19, 2020 With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 NCI Part of Federal Effort to Evaluate Antibody Tests for Novel... May 5, 2020 Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... December 6, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... The Most Successful Female Singer Of The 1970s Disappeared. Now She’s... Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds
